^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    5-genomic mutation signature

    i
    Other names: CREBBP, CBP, KAT3A, RSTS, RTS, CREB binding protein, KEAP1, Kelch Like ECH Associated Protein 1, Cytosolic Inhibitor Of Nrf2, Kelch-Like Family Member 19, Kelch-Like Protein 19, KLHL19, INrf2, KEAP1 Delta C, KIAA0132, INRF2, RAF1, Raf-1 Proto-Oncogene Serine/Threonine Kinase, RAF Proto-Oncogene Serine/Threonine-Protein Kinase, V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1, C-Raf Proto-Oncogene Serine/Threonine Kinase, Proto-Oncogene C-RAF, Raf-1, V-Raf-1 Murine Leukemia Viral Oncogene-Like Pr
    Entrez ID:
    7157; 6794; 9817; 5894; 1387
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost2years
    Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC. (PubMed, Lung Cancer)
    bGMS could predict OS benefit for patients with NSCLC receiving atezolizumab therapy. BGMS and other non-invasive clinical characteristics can be combined to develop a more accurate model.
    Clinical data • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • 5-genomic mutation signature
    |
    Tecentriq (atezolizumab) • docetaxel
    over2years
    A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab. (PubMed, Front Immunol)
    In addition, we compared the OS rate between patients receiving atezolizumab and docetaxel classified according to their risk score based on our gene mutation signature model. The 5-genomic mutation signature could predict OS benefit for patients with NSCLC receiving atezolizumab. Therefore, the establishment of the 5-genomic mutation panel will guide clinicians to identify optimal patients who could benefit from atezolizumab treatment.
    Clinical • Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • CREBBP (CREB binding protein)
    |
    PD-L1 expression • TP53 mutation • STK11 mutation • KEAP1 mutation • 5-genomic mutation signature
    |
    Tecentriq (atezolizumab) • docetaxel